δ-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients

Gonçalves, Thissiane L; Benvegnú, Dalila M; Bonfanti, Gabriela; Frediani, Andressa V; Rocha, João Batista T

doi:10.1186/1471-2407-9-138

BMC Cancer

Table 1 Characteristics of patients

From: δ-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients

Number of patients (n = 37)	Autologous PBSCT group II (n = 13)	Allogeneic BMT group III (n = 24)
Mean age (years)	48.15 ± 12.67^b	36.00 ± 16.08
Male	10	12
Female	03^b	12
Diagnosis
Multiple myeloma	03	01
Lymphoma Hodgkin	05	03
Lymphoma No Hodgkin	02	02
Leukemia
Leukemia Acute myeloid	01	02
Leukemia Chronic myeloid	00	07
Leukemia Acute lymphoblastic	01	01
Leukemia Chronic lymphoid	00	01
Myelodysplasia	00	05
Aplastic anemia	00	02
Tumor Ewing	01	00
Conditioning regimen
BuCy 120	01	13
BuCy 200	01	00
M-200	04	01
CBV	04	00
FluCy	00	05
BEAM	02	00
CyTBI	01	03
another	00	02

The CR patients were divided according to diseases. M-200: melphalan (200 mg/m²) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT. CBV: cyclophosphamide (1500 mg/m²) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU – 450 mg/m²) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 – 250 mg/m²) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU – 300 mg/m²) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 – 200 mg/m²) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m²) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m²) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT. FluCy: fludarabine (30 mg/m²) + cyclophosphamide (300 mg/m²), both given 3 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2) for Hodgkin and non-Hodgkin lymphomas in allogeneic BMT. BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT. BuCy200: busulphan (1 mg/kg), given 3 consecutive days four times a day, starting 9 days before the transplantation (days minus 9 to minus 7) + cyclophosphamide (50 mg/m²), given 4 consecutive days, starting 6 days before the transplantation (days minus 6 to minus 3) for aplastic anemia in allogeneic BMT. CyTBI: cyclophosphamide (60 mg/m²), given 2 consecutive days, starting 7 days before the transplantation (days minus 7 to minus 6) + total body irradiation, carried out on 4 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2, three times a day and day minus 1, two times a day) for acute and chronic lymphoid leukemia in autologous PBSCT or allogeneic BMT. All patients had 2 rest days (without chemotherapy) before the transplantation (days minus 2 and minus 1), except FluCy and CyTBI CR patients, that had only one rest day (day minus 1 and minus 5, respectively).
^b Significantly different between groups II (autol.) and III (allog.).

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com